Hysomide Injection can be administered intramuscularly (IM) or slowly intravenously (IV). For IV administration, inject slowly over at least 2 minutes to minimize the risk of acute dystonic reactions.

Hysomide acts primarily as a dopamine D2 receptor antagonist in the chemoreceptor trigger zone (CTZ) in the brain, thereby preventing nausea and vomiting. It also enhances gastrointestinal motility and tone by sensitizing muscarinic receptors and increasing acetylcholine release from cholinergic neurons, leading to increased gastric emptying and intestinal transit.

• •Hypersensitivity to Hysomide or any component of the formulation.
• •Gastrointestinal hemorrhage, obstruction, or perforation.
• •Pheochromocytoma (due to risk of hypertensive crisis).
• •Epilepsy, as it may increase seizure frequency.
• •History of tardive dyskinesia from dopamine antagonist treatment.

Store in a cool, dry place below 30°C. Protect from light. Do not freeze.

Symptoms of overdose may include drowsiness, disorientation, and extrapyramidal reactions (e.g., muscle rigidity, involuntary movements). Management involves symptomatic and supportive care. Anticholinergic drugs (e.g., diphenhydramine) or benzodiazepines may be used to control extrapyramidal symptoms.

Pregnancy Category B. Studies in animals have shown no evidence of harm to the fetus, but there are no adequate and well-controlled studies in pregnant women. Use only if clearly needed. Hysomide is excreted into breast milk; caution should be exercised when administered to a nursing mother.